Por: Forbes Business December 21, 2022
With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to , are looking to the pharmaceutical sector – a group typically prized for its recession resistance and supported by long-term demographics. Here’s a look at seven global favorites, focused on such areas as obesity and diabetes to new applications for mRNA-based vaccines. , Obesity is linked to more than 60 chronic diseases, including... + full article
Forbes USA Business November 28, 2022
Summary The third quarter of 2022 was another discouraging period for investors. Inflation kept going strong, the Federal Reserve continued raising interest rates and even the housing market began showing signs of weakness as consumers were slammed by the combination of rising... + más
Shaikin: Baseball embracing the 'flukes' and plenty of added revenue this postseason | Los Angeles Times
NFL Week 4: Across the league, teams have hit the ground running this year | The Boston Globe
The New York Times USA Business October 28, 2022
A few months ago, makers of seemed on top of the world.Customers could not get enough of the small slices of silicon, which act as the brains of computers and are needed in just about every device with an on-off switch. Demand was so strong — and U.S. dependence on a foreign... + más
Chip Stocks Are Crumbling. It’s Not Just the China Restrictions. | MarketWatch
A16 chip design means it's really an A15+, argues Macworld | 9to5Mac
The New York Times USA Health October 20, 2022
A Food and Drug Administration advisory committee on Wednesday recommended removing the drug Makena from the market, after years of study showed the fast-tracked drug had failed to prevent preterm births.Makena has been in use for 11 years, and the panel’s vote was widely of... + más
FDA panel recommends pulling preterm birth drug from the market | The Boston Globe
FDA panel recommends revoking the approval of controversial drug intended to prevent premature birth | CNBC
The Boston Globe USA Nation October 20, 2022
A Food and Drug Administration advisory committee on Wednesday recommended removing the drug Makena from the market, after years of study showed the fast-tracked drug had failed to prevent preterm birth.Makena has been in use for 11 years, and the panel’s vote was widely... + más
F.D.A. Panel Recommends Pulling Preterm Birth Drug From the Market | The New York Times
CNBC USA Health October 19, 2022
An advisory panel to the Food and Drug Administration voted Wednesday to take a drug intended to prevent premature births off the market, saying that it remains doubtful that the drug works.The recommendation, in a 14-1 vote, from the agency's Obstetrics, Reproductive and... + más
FDA panel backs removal of unproven pregnancy drug | WPLG Local 10
ALS drug wins FDA approval despite questionable data | ABC News
Fox Business USA Business October 03, 2022
Christopher McCann explains how the company doubled in size and 'significantly' grew its product offerings on 'The Claman Countdown.' The homecoming mum phenomenon has taken over the internet in recent years. The trendy fake flower makes an appearance once... + más
The Spirit of Ukraine | Bleacher Report
1 teen dead, 1 critically injured in high school homecoming game shooting | ABC News
CNBC USA Health September 29, 2022
The Food and Drug Administration on Thursday approved a controversial new drug designed to slow the progress of Lou Gehrig's disease, a victory for patients and advocates despite limited evidence that the drug is effective.The drug, from the Massachusetts-based , joins... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
About iurex | Privacy Policy | Disclaimer |